Bristol-Myers Squibb Announces Preliminary Court Approval of Derivative Settlement

Detailed Notice to Shareholders Available on Bristol-Myers Squibb Website

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the United States District Court for the Southern District of New York has granted preliminary approval of settlement of Sampson v. Robinson, et al., Case No. 1:07-CV-06890 (on appeal: Case No. 08-5475), a shareholder action pursued derivatively on behalf of Bristol-Myers Squibb. The action concerned allegations relating to the efforts to settle the Plavix patent litigation in 2006. The proposed settlement is subject to final Court approval. The Court has set a final approval hearing for December 8, 2009 at 2 p.m. in the courtroom of the Honorable Paul A. Crotty, United States District Judge.

As required by the Court’s Preliminary Approval Order, Bristol-Myers Squibb is providing shareholders with detailed notice of the terms of the proposed settlement on its website. The notice also contains important information regarding the rights of shareholders with respect to this proposed settlement. We encourage shareholders to read the notice in its entirety. The notice can be found at www.bms.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. For more information, visit www.bms.com.


Contacts
Bristol-Myers Squibb
Media:
Laura Hortas, 609-252-4587
laura.hortas@bms.com
or
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com
 

Posted: August 2009


View comments

Hide
(web4)